On March 22, British Columbia’s Ministry of Health announced that three new enoxaparin biosimilars, Valero Pharmaceuticals’ REDESCA, Juno Pharmaceuticals’ NOROMBY, and Sandoz’s INCLUNOX, would be covered by PharmaCare, the...more
In their respective third quarter financial results, Amgen and Pfizer both announced plans to seek interchangeable status for select biosimilars. Amgen announced that patients are currently being enrolled in Phase 3 studies...more
A study recently published in Cancer Communications reported that LY01008 or BOYOUNUO, a bevacizumab biosimilar developed by Shandong Boan Biotechnology Co., Ltd. (“Shandong Boan”), a subsidiary of Luye Pharma Group Ltd....more
On May 4, 2021, Amgen Canada announced the launch of their adalimumab biosimilar AMGEVITA (reference drug HUMIRA) for the treatment of 11 chronic inflammatory conditions. AMGEVITA is available as a prefilled syringe and a...more
On April 20, 2021, Korean company Huon Labs announced that it will develop a PROLIA biosimilar using PanGen Biotech’s cell culture and purification technology. PROLIA (denosumab), an Amgen product, is indicated to reduce the...more